Ekso Bionics Holdings, Inc. EKSO
We take great care to ensure that the data presented and summarized in this overview for EKSO BIONICS HOLDINGS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in EKSO
Top Purchases
Top Sells
About EKSO
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.
Insider Transactions at EKSO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 06
2024
|
Mary Ann Cloyd Director |
BUY
Grant, award, or other acquisition
|
Direct |
78,217
+26.18%
|
-
|
Jun 06
2024
|
Deborah Lafer Scher Director |
BUY
Grant, award, or other acquisition
|
Direct |
78,217
+50.0%
|
-
|
Jun 06
2024
|
Kecheng Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
78,217
+25.82%
|
-
|
Jun 06
2024
|
Corinna Lathan Director |
BUY
Grant, award, or other acquisition
|
Direct |
78,217
+25.69%
|
-
|
Mar 22
2024
|
Jerome Wong Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
7,474
+28.35%
|
-
|
Mar 22
2024
|
Jason C Jones Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
7,474
+24.64%
|
-
|
Nov 02
2023
|
Corinna Lathan Director |
BUY
Open market or private purchase
|
Direct |
4,032
+2.65%
|
$4,032
$1.24 P/Share
|
Aug 23
2023
|
Corinna Lathan Director |
BUY
Open market or private purchase
|
Direct |
5,500
+3.68%
|
$0
$0.95 P/Share
|
Aug 17
2023
|
Jerome Wong Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,784
-4.57%
|
$12,784
$1.0 P/Share
|
Aug 17
2023
|
Scott G. Davis President & COO |
SELL
Open market or private sale
|
Direct |
37,446
-10.15%
|
$37,446
$1.0 P/Share
|
Aug 10
2023
|
Corinna Lathan Director |
BUY
Open market or private purchase
|
Direct |
4,201
+2.94%
|
$4,201
$1.25 P/Share
|
Jun 12
2023
|
Jerome Wong Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
8,200
+41.81%
|
-
|
Jun 12
2023
|
Jerome Wong Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
170,068
+38.51%
|
-
|
Jun 12
2023
|
Jason C Jones Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
10,800
+41.39%
|
-
|
Jun 12
2023
|
Jason C Jones Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
190,454
+22.66%
|
-
|
Jun 08
2023
|
Mary Ann Cloyd Director |
BUY
Grant, award, or other acquisition
|
Direct |
72,993
+33.05%
|
-
|
Jun 08
2023
|
Kecheng Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
72,993
+32.42%
|
-
|
Jun 08
2023
|
Rhonda A. Wallen Director |
BUY
Grant, award, or other acquisition
|
Direct |
72,993
+33.05%
|
-
|
Jun 08
2023
|
Corinna Lathan Director |
BUY
Grant, award, or other acquisition
|
Direct |
72,993
+34.29%
|
-
|
Jun 08
2023
|
Steven Sherman Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
91,241
+16.67%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 328K shares |
---|